IQVIA Holdings — Connected Intelligence Platform Linking Clinical Data to Faster, Higher-Quality Trials
IQVIA Holdings, Inc., a Large Enterprise IT Services & Consulting company, achieved measurable value creation through Measurement and Analytics. Revenue growth: IQVIA grew from approximately $7.
| Company | IQVIA Holdings, Inc. |
| Industry | IT Services & Consulting |
| Company Size | Large Enterprise |
| Primary Lever | Measurement and Analytics |
| Key Result | Revenue growth: IQVIA grew from approximately $7 |
IQVIA was formed in 2016 from the merger of IMS Health and Quintiles Transnational Holdings. IMS Health possessed the world's largest commercial pharmaceutical database — aggregating prescription claims, physician activity, hospital purchasing, and real-world patient data from more than 100,000 data suppliers across 100+ countries. Quintiles was the world's largest contract research organization (CRO), running clinical trials for drug developers globally. Prior to the merger, neither company could fully use the other's core asset: Quintiles ran trials operationally but lacked the data to make patient recruitment and site selection decisions analytically; IMS had rich data assets but no delivery engine to turn them into trial outcomes. The combined entity, IQVIA, was formed explicitly to solve this gap. At formation, IQVIA had approximately $7.6B in combined revenue across technology solutions, research and development outsourcing, and commercial services.
IQVIA invested heavily in building its 'Connected Intelligence' platform — a proprietary technology architecture that fused IMS Health's data assets with Quintiles' trial delivery capabilities:
Paychex — Platform-Embedded Analytics Driving Revenue Per Client Growth
Total revenue growth: Revenue grew from $4
Cushman & Wakefield — Services Contract Discipline Driving Margin Expansion and Record Revenue
The contract discipline and operational restructuring produced measurable fin...
IMS Health's uniquely comprehensive pharmaceutical data assets — built over decades and covering prescription and treatment data for the majority of the world's pharmaceutical market — provided a competitive moat that no pure CRO competitor could replicate quickly. The merger was explicitly structured to capture this synergy, with senior leadership mandating cross-division data sharing within 12 months. Government and pharma regulatory pressure on trial efficiency (driven by FDA's concern about escalating drug development timelines) created external urgency for the analytics-driven improvements.
HCA Healthcare — Real-Time Clinical Analytics Reducing Sepsis Mortality Across 186 Hospitals
**22